Lotus Pharma Acquires Alpha Choay From Sanofi, Expands Southeast Asia Presence

Lotus Pharmaceutical has secured the rights to Alpha Choay (Chymotrypsine), including its trademark, marketing authorization, and manufacturing expertise, from Sanofi in Vietnam and Cambodia. This acquisition allows Lotus to take over the management of Alpha Choay's business in these regions right away. Once the deal is finalized, Lotus will gain full operational control of the product.

Lotus Pharmaceutical Co., Ltd. (TWSE: 1795), a global player in the pharmaceutical industry, has revealed that its Board of Directors has greenlighted the acquisition of Alpha Choay’s trademark, marketing rights, and manufacturing expertise in Vietnam and Cambodia from Sanofi. Once the transaction is finalized, Lotus will swiftly assume control of Alpha Choay’s operations in these markets, further strengthening its presence in Southeast Asia.

Alpha Choay has long been a trusted solution for treating edema caused by inflammation, injury, surgery, or burns in Vietnam. Recognized for its potent anti-inflammatory effects, the drug speeds up the healing process by promoting the reabsorption of edemas and hematomas, making it an essential part of postoperative care. In 2023, Alpha Choay generated over US$22 million in sales across Vietnam and Cambodia. With Lotus Pharmaceutical’s acquisition, the company is poised to leverage this success as it assumes full control of the product’s management and operations in both markets.

Petar Vazharov, CEO of Lotus, emphasized the strategic importance of the deal, saying, “This acquisition reflects our dedication to ensuring global access to high-quality medicines. Alpha Choay’s leading position in Vietnam’s anti-inflammatory market aligns with our mission and provides us with valuable entry into the local pharmacy sector, while strengthening our regional presence.” This is Lotus’s second acquisition in Southeast Asia this year, reinforcing its aggressive growth strategy as it seeks to establish a strong foothold in the Asia-Pacific market.

Lotus Pharmaceutical Co., Ltd. (1795: TT), established in 1966, is a leading global player in the pharmaceutical industry, known for its expertise in both novel and generic medications. With a robust R&D and manufacturing presence in Asia, the company has built strong alliances across key markets like the U.S., Europe, Japan, China, and Brazil. As a result, Lotus oversees more than 100 strategic projects in Asia and the U.S. and boasts a commercial portfolio exceeding 250 products.

The company is particularly focused on high-barrier drugs, including cutting-edge oncology treatments, complex generics, 505(b)(2) products, and New Chemical Entities (NCEs), driven by both in-house R&D and licensing efforts. Furthermore, Lotus is actively investing in biosimilars, leveraging partnerships with key strategic allies. Its operations are certified by major global regulatory bodies such as the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.

Sanofi, a leading global healthcare provider, is dedicated to delivering treatments and vaccines to people around the world, with a strong emphasis on sustainability and corporate responsibility. The company is listed on EURONEXT as SAN and on NASDAQ as SNY, reflecting its broad international presence. Its extensive portfolio spans a variety of therapeutic areas, focusing on managing and preventing a wide range of health conditions.

Sanofi offers diabetes treatments such as Lantus and Toujeo, oncology drugs like Libtayo for cancer care, and cardiovascular solutions like Praluent to control cholesterol levels. In addition, the company develops therapies for rare diseases, including Aldurazyme and Cerdelga, and provides vaccines such as Fluzone for flu prevention and Pentacel for multiple immunizations. Sanofi also plays a key role in neurology, offering treatments like Aubagio for multiple sclerosis and Dupixent for allergies and other related conditions.